Innovent Biologics Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
8,754
- Stock Symbol
-
01801
- Investments
-
5
- Share Price
-
$10.80
- (As of Friday Closing)
Innovent Biologics General Information
Description
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong Stock Exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
Contact Information
Website
www.innoventbio.comCorporate Office
- Number 168 Dongping Street, Suzhou Industrial Park
- Suzhou, Jiangsu 215123
- China
Corporate Office
- Number 168 Dongping Street, Suzhou Industrial Park
- Suzhou, Jiangsu 215123
- China
Innovent Biologics Timeline
Innovent Biologics Stock Performance
As of 13-Nov-2026, Innovent Biologics’s stock price is $10.80. Its current market cap is $18.8B with 1.74B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $10.80 | $11.10 | $8.87 - $14.38 | $18.8B | 1.74B | 11.7M | $0.10 |
Innovent Biologics Financials Summary
As of 30-Jun-2026, Innovent Biologics has a trailing 12-month revenue of $2.24B.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 15,423,145 | 15,995,610 | 6,993,816 | 8,231,917 |
| Revenue | 2,244,594 | 1,813,509 | 1,313,071 | 877,198 |
| EBITDA | 209,962 | 122,466 | (24,660) | (176,371) |
| Net Income | 176,122 | 113,132 | (13,188) | (145,291) |
| Total Assets | 6,125,230 | 5,337,922 | 2,959,220 | 2,909,934 |
| Total Debt | 341,935 | 402,443 | 387,809 | 510,754 |
Innovent Biologics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Innovent Biologics Comparisons
Industry
Financing
Details
Innovent Biologics Competitors (42)
One of Innovent Biologics’s 42 competitors is Abbisko Medicine, a Formerly VC-backed company based in Shanghai, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Abbisko Medicine | Formerly VC-backed | Shanghai, China | ||||
| CStone Pharmaceuticals | Formerly VC-backed | Suzhou, China | ||||
| Alphamab Oncology | Formerly VC-backed | Suzhou, China | ||||
| BeOne Medicines | Formerly PE-Backed | Beijing, China | ||||
| Incyte | Formerly VC-backed | Wilmington, DE |
Innovent Biologics Patents
Innovent Biologics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026233299-A1 | Methods of treating subjects having obesity | Pending | 06-May-2025 | ||
| WO-2026223801-A1 | Modified dsrna and use thereof | Pending | 25-Apr-2025 | ||
| WO-2026214626-A1 | Antigen-binding protein construct specifically binding to il-4rα and ox40l, and use thereof | Pending | 09-Apr-2025 | ||
| WO-2026214624-A1 | Method for preventing or treating inflammatory diseases | Pending | 09-Apr-2025 | ||
| WO-2026214625-A1 | Pharmaceutical composition comprising anti-il-4rα/tslp bispecific antibody and use thereof | Pending | 09-Apr-2025 |
Innovent Biologics Signals
Innovent Biologics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Innovent Biologics Investments (5)
Innovent Biologics’s most recent deal was a PE Growth/Expansion with IASO Biotechnology. The deal was made on 05-Jul-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| IASO Biotechnology | 05-Jul-2024 | PE Growth/Expansion | Drug Discovery | ||
| Affini-T | 17-Mar-2022 | Early Stage VC | Drug Discovery | ||
| Etana Biotechnologies Indonesia | 14-Sep-2021 | Later Stage VC | Biotechnology | ||
| AnHeart Therapeutics | 01-Sep-2021 | Early Stage VC | Biotechnology | ||
| Ascentage Pharma | 14-Jul-2021 | PIPE | Drug Discovery |
Innovent Biologics ESG
Risk Overview
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Innovent Biologics Exits (2)
Innovent Biologics’s most recent exit was on 17-Mar-2022 from Affini-T. The exit was categorized as with 13 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Affini-T | 17-Mar-2022 | Completed |
|
||
| AnHeart Therapeutics | 01-Sep-2021 | Early Stage VC | Completed |
|
Innovent Biologics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| InnoPinnacle | Shanghai, China | 2021 |
Innovent Biologics FAQs
-
When was Innovent Biologics founded?
Innovent Biologics was founded in 2011.
-
Where is Innovent Biologics headquartered?
Innovent Biologics is headquartered in Suzhou, China.
-
What is the size of Innovent Biologics?
Innovent Biologics has 8,754 total employees.
-
What industry is Innovent Biologics in?
Innovent Biologics’s primary industry is Pharmaceuticals.
-
Is Innovent Biologics a private or public company?
Innovent Biologics is a Public company.
-
What is Innovent Biologics’s stock symbol?
The ticker symbol for Innovent Biologics is 01801.
-
What is the current stock price of Innovent Biologics?
As of 13-Nov-2026 the stock price of Innovent Biologics is $10.80.
-
What is the current market cap of Innovent Biologics?
The current market capitalization of Innovent Biologics is $18.8B.
-
What is Innovent Biologics’s current revenue?
The trailing twelve month revenue for Innovent Biologics is $2.24B.
-
Who are Innovent Biologics’s competitors?
Abbisko Medicine, CStone Pharmaceuticals, Alphamab Oncology, BeOne Medicines, and Incyte are some of the 42 competitors of Innovent Biologics.
-
What is Innovent Biologics’s annual earnings per share (EPS)?
Innovent Biologics’s EPS for 12 months was $0.10.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process